Combination Immunotherapy for Type 1 Diabetes.
Combination Immunotherapy for Type 1 Diabetes.
复制标题
1型糖尿病的联合免疫疗法。
DOI：
10.1007/s11892-017-0878-z
复制
发表时间：
2017-07
影响因子：
4.2
通讯作者：
Evans-Molina C
中科院分区：
文献类型：
--
作者：
Bone RN;Evans-Molina C
Type 1 Diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T-cell or B-cell inhibition, regulatory T-cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation. The purpose of this review is to provide an overview and lessons learned from single immunotherapy trials, describe recent and ongoing combination immunotherapy trials, and provide perspectives on strategies for future combination clinical interventions aimed at preserving insulin secretion in T1D. Combination immunotherapies have had mixed results in improving short-term glycemic control and insulin secretion in recent-onset T1D. A handful of studies have successfully reached their primary end-point of improved insulin secretion in recent-onset T1D. However, long-term improvements glycemic control and the restoration of insulin independence remain elusive. Future interventions should focus on strategies that combine immunomodulation with efforts to alleviate β-cell stress and address the formation of antigens that activate autoimmunity.
登录
查看更多内容
影响因子：
7.7
作者：
Fisher MM;Watkins RA;Blum J;Evans-Molina C;Chalasani N;DiMeglio LA;Mather KJ;Tersey SA;Mirmira RG
通讯作者：
Mirmira RG
影响因子：
8.8
作者：
Bellin, M. D.;Kandaswamy, R.;Hering, B. J.
通讯作者：
Hering, B. J.
雷帕霉素对胰腺 β 细胞毒性的证据以及潜在分子机制的回顾。
影响因子：
7.7
作者：
Barlow AD;Nicholson ML;Herbert TP
通讯作者：
Herbert TP
影响因子：
7.7
作者：
Dudek, Nadine L.;Thomas, Helen E.;Kay, Thomas W. H.
通讯作者：
Kay, Thomas W. H.
影响因子：
3.7
作者：
Faustman, Denise L.;Wang, Limei;Nathan, David M.
通讯作者：
Nathan, David M.